Peficitinib was approved for use in Japan in 2019.[3]
Referencesedit
^Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, et al. (April 2017). "Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate". Arthritis & Rheumatology. 69 (4): 709–719. doi:10.1002/art.39955. PMID 27748083.
^Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, et al. (May 2017). "Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis". Arthritis & Rheumatology. 69 (5): 932–942. doi:10.1002/art.40054. PMID 28118538.
^Markham A, Keam SJ (June 2019). "Peficitinib: First Global Approval". Drugs. 79 (8): 887–891. doi:10.1007/s40265-019-01131-y. PMID 31093950. S2CID 155093525.
peficitinib, brand, name, smyraf, pharmaceutical, drug, used, treatment, rheumatoid, arthritis, belongs, class, drugs, known, janus, kinase, inhibitors, inhibitors, clinical, datatrade, namessmyrafother, namesasp015k, 54781532atc, codel04af06, legal, statusleg. Peficitinib brand name Smyraf is a pharmaceutical drug used for the treatment of rheumatoid arthritis It belongs to the class of drugs known as Janus kinase inhibitors JAK inhibitors 1 2 PeficitinibClinical dataTrade namesSmyrafOther namesASP015K JNJ 54781532ATC codeL04AF06 WHO Legal statusLegal statusIn general Prescription only IdentifiersCAS Number944118 01 8PubChem CID57928403UNIIHPH1166CKXKEGGD10721Chemical and physical dataFormulaC 18H 22N 4O 2Molar mass326 400 g mol 13D model JSmol Interactive imageSMILES NC O c1cnc2 nH ccc2c1NC1 C H 2CC3C C H 1CC O C3 C2InChI InChI 1S C18H22N4O2 c19 16 23 13 8 21 17 12 1 2 20 17 15 13 22 14 10 3 9 4 11 14 7 18 24 5 9 6 10 h1 2 8 11 14 24H 3 7H2 H2 19 23 H2 20 21 22 t9 10 11 1 YKey DREIJXJRTLTGJC JQCLMNFQSA N Y Peficitinib was approved for use in Japan in 2019 3 References edit Kivitz AJ Gutierrez Urena SR Poiley J Genovese MC Kristy R Shay K et al April 2017 Peficitinib a JAK Inhibitor in the Treatment of Moderate to Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate Arthritis amp Rheumatology 69 4 709 719 doi 10 1002 art 39955 PMID 27748083 Genovese MC Greenwald M Codding C Zubrzycka Sienkiewicz A Kivitz AJ Wang A et al May 2017 Peficitinib a JAK Inhibitor in Combination With Limited Conventional Synthetic Disease Modifying Antirheumatic Drugs in the Treatment of Moderate to Severe Rheumatoid Arthritis Arthritis amp Rheumatology 69 5 932 942 doi 10 1002 art 40054 PMID 28118538 Markham A Keam SJ June 2019 Peficitinib First Global Approval Drugs 79 8 887 891 doi 10 1007 s40265 019 01131 y PMID 31093950 S2CID 155093525 Portal nbsp Medicine nbsp This antineoplastic or immunomodulatory drug article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Peficitinib amp oldid 1199609586, wikipedia, wiki, book, books, library,
